glenmark

PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com

CIN: L24299MH1977PLC019982

Statement of Audited Financial Results for the Quarter and Year Ended 31 March, 2019

			Sta	ndalone (Ind A	S)		Consolidated (Ind AS) Consolidated (IF				nsolidated (IFR	FRS)				
	Particulars (Refer notes below)	Quarter ended 31-03-2019 (Audited)	Quarter ended 31-12-2018 (Unaudited)	Quarter ended 31-03-2018 (Audited)	Year ended 31-03-2019 (Audited)	Year ended 31-03-2018 (Audited)	Quarter ended 31/03/2019 (Audited)	Quarter ended 31/12/2018 (Unaudited)	Quarter ended 31/03/2018 (Audited)	Year ended 31/03/2019 (Audited)	Year ended 31/03/2019 (Audited)	Quarter ended 31/03/2019 (Audited)	Quarter ended 31/12/2018 (Unaudited)	Quarter ended 31/03/2018 (Audited)	Year ended 31/03/2019 (Audited)	Year ended 31/03/2018 (Audited)
	Revenue from operations															
	(a) Net sales	15,307.63	15,998.97	13,072.07	61,311.40	52,434.15	25,260.82	25,097.79	22,478.93	97,050.84	89,722.32	25,260.82	25,097.79	22,478.93	97,050.84	89,722.32
	(b) Other operating income	565.16	321.39	1,389.47	1,737.27	3,007.93	373.92	452.66	319.23	1,603.84	1,308.38	373.92	452.66	319.23	1,603.84	1,308.38
Ш.,	Total revenue from operations	15,872.79	16,320.36	14,461.54	63,048.67	55,442.08 1,799.92	25,634.74	25,550.45	22,798.16	98,654.68	91,030.70 914.00	25,634.74	25,550.45	22,798.16	98,654.68	91,030.70
	Other income Total income (I + II)	1,683.89 17,556.68	(846.41) 15,473.95	439.61 14,901.15	4,756.14 67,804.81	57,242.00	390.57 26,025.31	(1,090.15) 24,460.30	695.52 23,493.68	2,081.37 1,00,736.05	91,944.70	390.58 26,025.32	(1,090.24) 24,460.21	695.52 23,493.68	2,081.12 1,00,735.80	914.00 91,944.70
II IV	Expenses	17,550.00	15,475.55	14,501.13	07,004.01	37,242.00	20,025.51	24,400.50	23,433.00	1,00,730.03	31,344.70	20,023.32	24,400.21	20,493.00	1,00,733.00	31,344.70
II ''	(a) Cost of materials consumed	2,548.89	5,365.47	4,568.55	15,858.51	16,480.25	6,144.64	7,318.05	6,149.42	24,447.12	21,501.10	6,144.64	7,318.05	6,149.42	24,447.12	21,501.10
Ш	(b) Purchase of stock-in-trade	476.85	908.24	632.69	3,012.95	2,881.77	1,718.19	2,914.14	1,734.00	9,762.98	7,547.45	1,718.19	2,914.14	1,734.00	9,762.98	7,547.45
Ш	(c) Changes in inventories of finished goods,					_,			,	,	.,					
	work-in-progress and stock-in-trade	3,168.80	(24.78)	275.75	4,718.11	1,397.14	744.39	(1,612.05)	(40.39)	(586.68)	1,337.12	744.39	(1,612.05)	(40.39)	(586.68)	1,337.12
Ш	(d) Employee benefits expense	2,242.26	2,320.86	2,046.92	9,699.80	8,956.71	4,945.85	5,030.81	4,642.73	20,560.70	18,718.41	4,945.85	5,030.81	4,642.73	20,560.70	18,718.41
	(e) Finance costs	526.08	551.82	507.22	2,238.14	1,908.98	819.11	885.35	743.88	3,345.85	2,855.67	819.11	885.35	743.88	3,345.85	2,855.67
Ш	(f) Depreciation and amortisation expense	263.48	257.04	238.72	1,062.79	959.27	809.70	831.01	735.32	3,259.05	3,018.76	871.24	935.58	894.24	3,685.27	3,540.67
Ш	(g) Other expenses	4,748.51	4,257.02	4,131.46	16,484.52	14,716.17	8,440.36	7,552.70	7,044.05	28,612.56	25,772.89	8,440.36	7,552.70	7,046.35	28,612.56	25,776.33
Ι,	Total expenses (IV)	13,974.87	13,635.67	12,401.31	53,074.82	47,300.29	23,622.24	22,920.01	21,009.01	89,401.58	80,751.40	23,683.78	23,024.58	21,170.23	89,827.80	81,276.75
V V	Profit/(loss) before exceptional items and tax (III - IV) Exceptional items (Refer note 7)	3,581.81	1,838.28	2,499.83	14,729.99 (3,451.85)	9,941.71	2,403.07	1,540.29	2,484.67	11,334.47 (1,671.82)	11,193.30	2,341.54	1,435.63	2,323.45	10,908.00 (1,671.82)	10,667.95
VII	Profit/(loss) before tax (V - VI)	3,581.81	1,838.28	2,499.83	18,181.84	9,941.71	2,403.07	1,540.29	2,484.67	13,006.29	11,193.30	2,341.54	1,435.63	2,323.45	12,579.82	10,667.95
VIII	Tax expense :	0,001.01	1,000.20	2,400.00	10,101.04	0,041.71	2,400.07	1,540.25	2,404.07	10,000.25	11,100.00	2,041.04	1,400.00	2,020.40	12,070.02	10,007.00
	Current tax	848.44	309.32	598.40	3,834.95	2,018.21	874.25	629.89	961.43	4,765.42	3,256.90	874.25	629.89	948.64	4,765.42	3,244.11
Ш	Deferred tax	(79.51)	(165.26)	(22.30)	(536.14)	(735.11)	(87.80)	(253.01)	6.97	(1,009.06)	(102.30)	(95.68)	(270.93)	(135.56)	(1,102.30)	(318.99)
IX	Profit/(loss) for the period from continuing operations (VII-VIII)	2,812.88	1,694.22	1,923.73	14,883.03	8,658.61	1,616.62	1,163.41	1,516.27	9,249.93	8,038.70	1,562.97	1,076.67	1,510.37	8,916.70	7,742.83
X	Profit/(loss) before tax from discontinuing operations	_	398.25	440.86	2,028.34	2,246.54	-	-	-	-	-	-	-	-	-	-
X	Tax expense of discontinuing operations :		555565	2000 2000	C1070700	700000000000000000000000000000000000000										
	Current tax	-	119.25	135.12	650.29	688.56	-	-	-	-	-	-		-	-	-
,	Deferred tax		14.51	14.35	39.96	73.12		100	-		-	-			-	14
XII	Profit/(loss) for the period from discontinuing operations (X-XI)	-	264.49	291.39	1,338.09	1,484.86			-	-	**	-			**	
XIII	Profit/(loss) for the period for continuing and discontinuing operations (IX + XII)	2,812.88	1,958.71	2,215.12	16,221.12	10,143.47	1,616.62	1,163.41	1,516.27	9,249.93	8,038.70	1,562.97	1,076.67	1,510.37	8,916.70	7,742.83
NIX I	Other comprehensive income	2,012.00	1,000.71	2,210.12	10,221.12	10,140.47	1,010.02	1,100.41	1,010.27	0,240.00	0,000.70	1,002.07	1,070.07	1,010.07	0,010.70	7,742.00
1000	A (i) Items that will not be reclassified to profit or loss	(13.42)	(17.61)	36.41	(54.38)	(10.20)	(274.54)	(16.69)	9.93	(259.39)	41.96	(274.54)	(16.69)	9.93	(259.39)	41.96
Ш	(ii) Income tax relating to items that will not be	**********	27.000.00	700000000	105000000000	275.000	1.500.0000014		50000000000000000000000000000000000000			************	************	10000000000000000000000000000000000000	55 (425) (455, 435) 645, 437, 657	100000000
Ш	reclassified to profit or loss	4.69	6.15	(12.60)	19.00	3.53	38.78	6.03	(9.15)	45.80	(3.25)	38.78	6.03	(9.15)	45.80	(3.25)
Ш	B (i) Items that will be reclassified to profit or loss		(*)		1.5	15	(951.38)	566.06	(511.28)	(3,710.57)	(778.78)	(948.75)	527.52	(463.92)	(3,732.65)	(696.17)
Ш	(ii) Income tax relating to items that will be reclassified to profit or loss		46.0		75	80	(200.25)	/EC 02\		(229.50)		(300.25)	(56.92)	0.000	(220 50)	500
II xv	Total comprehensive income	2,804.15	1,947.25	2,238.93	16,185.74	10,136.80	(300.25) 129.23	(56.92) 1,661.89	1,005.77	5,096.27	7,298.63	78.21	1,536.61	1,047.23	(229.50) 4,740.96	7,085.37
	Total comprehensive income attributable to:	2,004.13	1,547.25	2,200.00	10,103.74	10,100.00	125.25	1,001.03	1,000.77	3,030.27	7,230.00	70.21	1,556.01	1,047.20	4,740.30	7,000.07
	- Non-controlling interests		-		-	-	0.10	0.09	0.47	0.11	0.92	0.10	0.09	0.47	0.11	0.92
ш	- Owners of the Company	2,804.15	1,947.25	2,238.93	16,185.74	10,136.80	129.13	1,661.80	1,005.30	5,096.16	7,297.71	78.11	1,536.52	1,046.76	4,740.85	7,084.45
XVI	Other equity	-		- SSSS	1,19,138.72	1,03,632.24		100		55,769.67	51,352.60				59,670.14	55,608.37
XVI	Earning per share (EPS) (for continuing operations)															
	(of Re 1/- each) (not annualised for quarters)	0.07	0.00	0.00	50.75	00.00				00.70	00.40			- 05	04.00	07.44
	Basic EPS (in Rupees)	9.97	6.00	6.82	52.75	30.69	5.73 5.73	4.12	5.37	32.78	28.49	5.54	3.82	5.35	31.60	27.44
XIX	Diluted EPS (in Rupees) Earning per share (EPS) (for discontinuing operations)	9.97	6.00	6.82	52.74	30.69	5./3	4.12	5.37	32.78	28.49	5.54	3.82	5.35	31.60	27.44
^1^	(of Re 1/- each) (not annualised for quarters)															
	Basic EPS (in Rupees)	-	0.94	1.03	4.74	5.26		1941		538.0		100		-	-	:-
	Diluted EPS (in Rupees)	-	0.94	1.03	4.74	5.26		11.5	-			2.5			5.	
XX	Earning per share (EPS) (for continuing and discontinuing															
	operations) (of Re 1/- each) (not annualised for quarters)	I .														
	Basic EPS (in Rupees)	9.97	6.94	7.85	57.49	35.95	5.73	4.12	5.37	32.78	28.49	5.54	3.82	5.35	31.60	27.44
	Diluted EPS (in Rupees)	9.97	6.94	7.85	57.49	35.95	5.73	4.12	5.37	32.78	28.49	5.54	3.82	5.35	31.60	27.44

- 1. The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July, 2016. The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the IFRS in the format as per the Regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015.
- 2 The above results were reviewed by the Audit Committee at its meeting held on 28 May, 2019 and approved at the meeting of the Board of Directors held on 29 May, 2019.
- In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the statutory auditors have performed an audit of the standalone and consolidated financial results of the Company for the financial year ended 31 March, 2019. There are no modifications in the audit report.
- The figures for the quarter ended 31 March are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the figures for the third quarter of the relevant financial year.
- On 1 January 2019, the Company completed the transfer of the Company's Active Pharmaceuticals Ingredient (API) business to Glenmark Life Sciences Limited, a wholly owned subsidiary of the Company. 6 During the year, the Company bought back U.S.\$86,500,000 in aggregate principal amount of the Foreign Currency Convertible Bonds (FCCB). As of 31
- March, 2019, U.S.\$113,500,000 in aggregate principal amount of FCCB are outstanding, resulting in gain on extinguishment of liability of Rs. 153.72 million. Exceptional item: Exceptional items in the standalone (Ind AS) financial results for the year ended 31 March, 2019, primarily comprises of net gain of Rs. 3,451.85 million towards the sale of Orthopaedic and Pain management India business (Ortho India business). Exceptional items in the consolidated financial results (Ind AS and IFRS) for the year ended 31 March 2019 primarily comprises of the gain of Rs. 3,451.85 million towards the sale of Ortho India business and effect of de-prioritization of certain intangibles aggregating to Rs. 1,780.03 million.
- 8 Post implementation of Goods and Service Tax ('GST') with effect from 1 July, 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in GST. Revenue from operations for year ended 31 March, 2018 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for quarter and year ended 31 March, 2019 are not comparable with previous periods presented.
- 9 The disclosure of statement of assets and liabilities as per Regulation 33(3)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are an integral part of these results.
- 10 The Board has recommended a final dividend of 200% .i.e. Rs. 2 per equity share of face value of Re. 1 each for financial year 2018-19. The payment is subject to the approval of the shareholders in the ensuing annual general meeting.
- 11 Effective 1 April, 2018, the Company adopted Ind AS 115 or IFRS 15 "Revenue from Contracts with customers", as the case may be using the modified retrospective transition method. There was no material effect on the financial results on adoption of Ind AS 115 or IFRS 15, as the case may be.
- 12 The list of subsidiaries as of 31 March, 2019 is provided in Annexure A. 13 The Company operates in one reportable business segment i.e., Pharmaceuticals.
- 14 As at 31 March, 2019, pursuant to Employee Stock Options Scheme 2016, 4,59,414 options were outstanding, which upon exercise are
- convertible into equivalent number of equity shares.
- 15 Diluted EPS has been computed considering the effect of conversion of ESOPs.
- 16 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Glenmark Pharmaceuticals Limited

Annexure A List of entities included in the consolidated financial results for the year ended 31 March 2019

 Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2.Glenmark Pharmaceuticals Europe Ltd., U.K. 3.Glenmark Pharmaceuticals S.R.O. 4.Glenmark Pharmaceuticals SK, S.R.O. 5.Glenmark Pharmaceuticals S. A. 6.Glenmark Holding S.A. 7.Glenmark Pharmaceuticals S.R.L. 8.Glenmark Pharmaceuticals SP z.o.o. 9.Glenmark Pharmaceuticals Inc. (formerly Glenmark Generics Inc.) 10.Glenmark Therapeutics Inc. 11.Glenmark Farmaceutica Ltda 12.Glenmark Generics S.A 13.Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 14.Glenmark Pharmaceuticals Peru SAC 15. Glenmark Pharmaceuticals Colombia SAS, Colombia (Formerly known as Glenmark Pharmaceuticals Colombia Ltda., Colombia) 16.Glenmark Uruguay S.A. 17.Glenmark Pharmaceuticals Venezuela, C.A 18.Glenmark Dominicana SRL 19.Glenmark Pharmaceuticals Egypt S.A.E. 20.Glenmark Pharmaceuticals FZE 21.Glenmark Impex L.L.C 22.Glenmark Philippines Inc. 23.Glenmark Pharmaceuticals (Nigeria) Ltd. 24.Glenmark Pharmaceuticals Malaysia Sdn Bhd 25.Glenmark Pharmaceuticals (Australia) Pty Ltd 26.Glenmark South Africa (pty) Ltd 27.Glenmark Pharmaceuticals South Africa (pty) Ltd 28.Glenmark Pharmaceuticals (Thailand) Co. Ltd 29.Glenmark Pharmaceuticals B.V.(Formerly known as Glenmark Generics B.V.) 30.Glenmark Arzneimittel Gmbh 31.Glenmark Pharmaceuticals Canada Inc. (formerly Glenmark Generics Canada Inc.) 32. Glenmark Pharmaceuticals Kenya Ltd 33. Glenmark Therapeutics AG 34. Viso Farmaceutica S.L., Spain 35. Glenmark Specialty SA 36. Glenmark Pharmaceuticals Distribution s.r.o. 37. Glenmark Pharmaceuticals Nordic AB 38. Glenmark Ukraine LLC 39.Glenmark-Pharmaceuticals Ecuador S.A. 40.Glenmark Pharmaceuticals Singapore Pte. Ltd. 41.Glenmark Biotherapeutics SA 42.Glenmark Life Sciences Limited (Formerly known as Zorg Laboratories Private Limited)

Glenmark Pharmaceuticals Limited Statement of assets and liabilities

(All amounts in million of Indian Rupees, unless otherwise stated)

(All altrounts in million of indian mapees, diffess otherwise		ALONE	CONSOLIDATED						
	Ind AS As at 31.03.2019 Audited	Ind AS As at 31.03.2018 Audited	Ind AS As at 31.03.2019 Audited	Ind AS As at 31.03.2018 Audited	IFRS As at 31.03.2019 Audited	IFRS As at 31.03.2018 Audited			
ASSETS									
Non current assets									
Property, plant and equipment	13,081.67	15,766.49	20,978.12	18,958.10	23,688.89	21,733.74			
Capital work-in-progress	2,091.79	3,540.42	12,343.68	9,933.40	12,708.34	10,347.15			
Goodwill			547.35	521.04	547.35	521.04			
Other intangible assets	1,053.16	1,224.73	15,177.07	10,816.38	17,289.96	13,296.47			
Intangible assets under development	770.16	656.33	1,645.70	1,285.32	1,645.70	1,285.32			
Financial assets	1,10.10	000.00	1,010.70	1,200.02	1,010.10	1,200.02			
(i) Investments	32,687.52	32,126.84	296.59	146.61	296.59	146.61			
(ii) Loans and advances	62,639.26	33,028.48	200.00		200.00				
(iii) Other financial assets	368.01	380.91	501.87	401.18	501.87	401.18			
Deferred tax assets (net)	7,121.33	6,606.15	13,829.51	13,202.60	12,905.43	12,201.76			
Other non-current assets	202.54	565.85	599.77	802.23	236.00	389.36			
Total non- current assets	1,20,015.44	93,896.20	65,919.66	56,066.86	69,820.13	60,322.63			
Current assets	1,20,010.44	00,000.20	00,010.00	00,000.00	00,020.10	00,022.00			
Inventories	9,112.09	11,111.80	22,520.74	20,305.85	22,520.74	20,305.85			
Financial assets	3,112.03	11,111.00	22,020.74	20,000.00	22,020.74	20,000.00			
(i) Investments									
(ii) Trade receivables	20,871.31	38,289.08	21,945.90	23,318.07	21,945.90	23,318.07			
(iii) Cash and cash equivalents	2,549.97	1,760.47	9,362.78	12,333.56	9,362.78	12,333.56			
(iv) Bank balance other than cash and cash equivalents	14.87	13.35	14.87	13.35	14.87	13.35			
(v) Other financial assets	13,123.42	1,937.10	2,802.66	3,856.42	2,802.66	3,856.42			
Current tax assets	10,120.42	1,007.10	2,002.00	3,030.42	2,002.00	3,030.42			
Other current assets	5,739.87	5,640.71	10,321.30	10,059.67	10,321.30	10,059.67			
Total current assets	51,411.53	58,752.51	66,968.25	69,886.92	66,968.25	69,886.92			
Total assets	1,71,426.97	1,52,648.71	1,32,887.91	1,25,953.78	1,36,788.38	1,30,209.55			
EQUITY AND LIABILITIES	1,71,420.37	1,02,040.71	1,02,007.31	1,20,000.70	1,00,700.00	1,00,200.00			
Equity									
Equity share capital	282.17	282.17	282.17	282.17	282.17	282.17			
Other equity	1,19,138.72	1,03,632.24	55,769.67	51,352.60	59,670.14	55,608.37			
Minority interest	1,10,100.72	1,00,002.24	(3.77)	(3.70)	(3.77)	(3.70)			
Liabilities	157.	0.70	(0.77)	(3.70)	(5.77)	(5.70)			
Non-current liabilities									
Financial liabilities									
(i) Borrowings	28,314.52	26,860.29	35,737.54	41,417.78	35,737.54	41,417.78			
(ii) Other financial liabilities	885.06	26.00	885.06	26.00	885.06	26.00			
Deferred tax liabilities (net)	005.00	20.00	005.00	20.00	005.00	20.00			
Other non- current liabilities			6.30		6.30	- 1			
Total non-current liabilities	29,199.58	26,886.29	36,628.90	41,443.78	36,628.90	41,443.78			
Current liabilities	29,199.30	20,000.29	30,020.90	41,443.70	30,020.90	41,443.70			
Financial liabilities	2 020 20	2.050.44	3,030.24	2.050.44	2 020 24	2.050.44			
(i) Borrowings	3,030.30	2,950.44	110 L 1 10 10 10 10 10 10 10 10 10 10 10 10 1	2,950.44	3,030.24	2,950.44			
(ii) Other financial liabilities	1,412.12	1,848.86	9,012.69	5,657.89	9,012.69	5,657.89			
(iii) Trade payables									
Total outstanding dues of other than Micro enterprises		44.574.00	04 007 50	47.740.50	04 007 50	47.740.50			
and Small enterprises	15,787.57	14,571.28	21,097.52	17,719.59	21,097.52	17,719.59			
Total outstanding dues of Micro enterprises and			4 444 45						
Small enterprises	889.07	978.25	1,109.99	978.25	1,109.99	978.25			
Other current liabilities	469.90	567.19	1,119.44	1,248.12	1,119.44	1,248.12			
Provisions	853.30	783.58	4,383.50	4,040.38	4,383.50	4,040.38			
Current tax liabilities (Net)	364.24	148.41	457.56	284.26	457.56	284.26			
Total current liabilities	22,806.50	21,848.01	40,210.94	32,878.93	40,210.94	32,878.93			
Total lightilities	52,006.08	48,734.30	76,839.84	74,322.71	76,839.84	74,322.71			
Total liabilities Total equity and liabilities	1,71,426.97	1,52,648.71	1,32,887.91	1,25,953.78	1,36,788.38	1,30,209.55			

For and on behalf of the Board of Directors

Glenn Saldanha Chairman & Managing Director

CLASSIFIED CENTRES IN MUMBAI

Pallavi Advig. Dadar (W), Mobile: 9869109765 Shree Swami Samarth Advertising, Dadar (W), Phone: 24440631 Mobile: 9869131962

Mumbai, 29 May, 2019

Media Junction, Matunga (W), Phone: 022-66393184/ 022-66332340 Mobile: 9820295353/ 9821656198 Space Age Advertising. Phone: 26552207 Mobile: 9869666222 Kirti Agencies, Khar (W), Phone: 26047542. Krishna Advertising.

Gauri Press Communication, Phone: 2617 6310 Mobile: 9820069565 Carl Advertising. Lokhandwala Advertixing, Andheri (W), Phone: 26364274 / 26316960.

Phone: 022-26288794 Mobile: 9833364551/ 9820199918 P. V. Advertisers. Goregaon (E), Phone : 2927 5033. Mobile : 9819099563. Adresult Services, Goregaon (W) Phone: 28762157 / 28726291. Samartha Advertiser Pvt. Ltd., Target Media.

New Boom Adx, Kandivali (W), Phone : 28640221. Goregaon (E), Mobile: 8692959648/ 9702307711 Pranav Publicity, Kandivali (W) Phone: 42759999, Mobile: 9820295421. Bijal Visual Ads. Malad (W), Phone: 28835457/ 28805487 Mobile: 9322265715 Vikxon Advertixing Agency Kandivali (W), Noble Publicity Service, Malad (W), Phone: 28881426 / 28881518.

Arthant Advertising, Kandivali (W) Phone: 28626679 Mobile: 9004992568

Synergy Advertising, Malad (W), Phone: 28891428 / 22811012

Express Advertising, Borivali (W), Phone: 2833 7799 /2833 9977, Mobile: 9820401077 Falcon Multimedia Pvt. Ltd., Rorivali (E) Mobile : 9833226463 Nikharge Advertising, Borivali (W), Phone : 28921255 Mobile : 9322210176 Ashansi Advertising & Press Relations, Mira Road (E). Phone: 022-28114235 Mobile: 9833933502 M.S. Advertising.

Bhayander (E). Phone: 022-28160100 Mobile: 9769711727

Sugo Advertising, Vasai (W), Phone: 7756982329/ 7028565571 Mayuresh Publicity, Virar (W), Phone: 0250 = 2503913, Mobile: 9923935556 Plaxma Advertising, Panvel, Phone : 022-27461970 Phone: 71012345 Mobile: 9324102060/ 9820152753 Rahul Advertising Vasht, Phone: 022-65119998 Mobile: 9820200044

Shark Enterprises, Goregaon (E), Phone: 022-26863587 Classifieds

Dadar (W), Phone : 24304897 Time Advertising.

Andheri (W), Phone: 6696 3441 / 42. Prime Publicity Services. Santacruz (E), Phone: 26651754 Mobile: 9324868171. Andheri (E), Phone : 26839686 / 26830304.

Making A Small Message Go A Long Way



प्रतिनिधी, मुंबई

शिवाजी छत्रपती महाराज टर्मिनस स्थानकाबाहेरचा हिमालय पुल हा अति गंजल्यानेच कोसळला, असा अहवाल वीर जिजाबाई अभियांत्रिकी संस्थेने (व्हीजेटीआय) सादर केला आहे. पोलिसांनी गुरुवारी या प्रकरणी पुरवणी आरोपपत्र सादर केले. त्यात या

अहवालाचा समावेश आहे.

पालिकेचे तीन अधिकारी आणि एका खासगी संरचनात्मक पाहणी कंपनीच्या प्रमुखाला पोलिसांनी निष्काळजीपणा केल्याप्रकरणी अटक केली आहे. पूल दुर्घटनेनंतर पोलिसांनी 'व्हीजेटीआय'ला पूल कोसळण्याची कारणमीमांसा करण्यास सांगितले होते. पोलिसांनी गुरुवारी या प्रकरणी ३०६

अति गंजल्यानेच हिमालय पूल कोसळला

'व्हीजेटीआय'चा अहवाल, पुरवणी आरोपपत्र दाखल

पानांचे पुरवणी आरोपपत्र सादर या अहवानुसार, पूल अति गंजला करताना त्यात 'व्हीजेटीआय'च्या होता, पुलाच्या लोखंडाची जाडी

अहवालाचा प्रामुख्याने दाखला दिला. गंजामुळे कमी झाली होती. तो विभागाचे कार्यकारी आणि साहाय्यांक

अभियंता अनिल पाटील, एस. एफ. काळकुते यांच्यासह पालिकेचे माजी मुख्य अभियंता शीतलाप्रसाद कोरी कोसळण्यामागे हेही प्रमुख कारण होते. आणि पुलाची संरचनात्मक पाहणी आरोपींमध्ये पालिकेच्या पूल करणाऱ्या कंपनीचा प्रमुख नीरज देसाई

यांचा समावेश आहे. पुरवणी आरोपपत्रानुसार, ऑक्टोबर २०१६ मध्ये तत्कालिन पालिका आयुक्त अजोय मेहता यांनी पुलाला भेट दिली होती. स्वच्छ भारत अभियानाअंर्तगत या पुलाचे सुशोभीकरणाचे आदेश दिले होते. त्याबाबतचे पत्र पाटील यांना पाठवण्यात आले होते. त्यात सुशोभीकरणाचे काम करण्याआधी

पुलाची संरचनात्मक पाहणी करण्यास सांगण्यात आले आहे. परंतु पाटील यांनी त्याकडे दुर्लक्ष केले. अभियंत्यांनी पावसाळ्यापूर्वी आणि पावसाळ्यानंतर पुलाची पाहणी करणे अनिवार्य आहे. परंतु आरोपींनी ते काम केलेच नाही. कोरी यांनीही आवश्यक ती पाहणी केली नाही, असा दावा पोलिसांनी केला आहे.

glenmark

PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com

CIN: L24299MH1977PLC019982

Statement of Audited Financial Results for the Quarter and Year Ended 31 March. 2019

	Statement of Audi	iteu i	man	Ciai i	iesu	113 10	i tile	Quai	tei a	ma iv	cai L	indec	1311	viaici	1, 20	(さ in Millions)
	000000000000000000000000000000000000000	Standalone (Ind AS)					Consolidated (Ind AS)					Consolidated (IFRS)				
	Particulars (Refer notes below)	Quarter ended 31-03-2019 (Audited)	Quarter ended 31-12-2018 (Unaudited)	Quarter ended 31-03-2018 (Audited)	Year ended 31-03-2019 (Audited)	Year ended 31-03-2018 (Audited)	Quarter ended 31/03/2019 (Audited)	Quarter ended 31/12/2018 (Unaudited)	Quarter ended 31/03/2018 (Audited)	Year ended 31/03/2019 (Audited)	Year ended 31/03/2019 (Audited)	Quarter ended 31/03/2019 (Audited)	Quarter ended 31/12/2018 (Unaudited)	Quarter ended 31/03/2018 (Audited)	Year ended 31/03/2019 (Audited)	Year ended 31/03/2018 (Audited)
-	Revenue from operations	45 007 00	45 000 07	10.070.07	01 011 10	50 424 45	05.000.00	05 007 70	00 470 00	07.050.04	20 700 00	05 000 00	25 207 70	20, 470,00	07.050.04	00 700 00
	(a) Net sales (b) Other operating income	15,307.63 565.16	15,998.97 321.39	13,072.07 1,389.47	61,311.40 1,737.27	52,434.15 3,007.93	25,260.82 373.92	25,097.79 452.66	22,478.93 319.23		89,722.32 1,308.38	25,260.82 373.92	60.771.070.070.070.750.75	22,478.93 319.23	2015.00.000.000	89,722.32 1,308.38
	Total revenue from operations	15,872.79	16,320.36	14,461.54	63,048.67	55,442.08	25,634.74	25,550.45	22,798.16		91,030.70	25,634.74		22,798.16		91,030.70
	Other income	1,683.89	(846.41)	439.61	4,756.14	1,799.92	25-36-100-000-000-00	(1,090.15)	695.52	2000/04/2003 (19950) 47 00	914.00		100000000000000000000000000000000000000	695.52	0.000 0	914.00
III	Total income (I + II)	17,556.68	15,473.95	14,901.15	67,804.81	57,242.00	26,025.31	24,460.30	23,493.68	202.500.0000.000	91,944.70	26,025.32		23,493.68	50 10 10 10 10 10 10 10 10 10 10 10 10 10	91,944.70
IV	Expenses	82.76 2300.200	12/15/14/16/15/16/16/16/16/16/16/16/16/16/16/16/16/16/				1		1		100000000000000000000000000000000000000		1	100000000000000000000000000000000000000	33.355.05000000000000000000000000000000	100000000000000000000000000000000000000
	(a) Cost of materials consumed	2,548.89	5,365.47	4,568.55	15,858.51	16,480.25	6,144.64	7,318.05	6,149.42	24,447.12	21,501.10	6,144.64	7,318.05	6,149.42	24,447.12	21,501.10
	(b) Purchase of stock-in-trade	476.85	908.24	632.69	3,012.95	2,881.77	1,718.19	2,914.14	1,734.00	9,762.98	7,547.45	1,718.19	2,914.14	1,734.00	9,762.98	7,547.45
,	(c) Changes in inventories of finished goods,		(5.1.70)			, , , , , , , , , , , , , , , , , , , ,	1	1	1	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1			/	1	1
,	work-in-progress and stock-in-trade	3,168.80	(24.78)	275.75	4,718.11	1,397.14		(1,612.05)	(40.39)		1,337.12	A. J. J. J. S.	1,7,7	(40.39)		1,337.12
	(d) Employee benefits expense	2,242.26	2,320.86	2,046.92	9,699.80	8,956.71	4,945.85	5,030.81	4,642.73	1900 (* E. C.) (1900 (1900)	18,718.41	4,945.85	200 Tent (0.676 to	4,642.73	N 1000 (100 (100 (100 (100 (100 (100 (10	18,718.41
- 1	(e) Finance costs	526.08 263.48	551.82 257.04	507.22 238.72	2,238.14 1,062.79	1,908.98 959.27	819.11 809.70	885.35 831.01	743.88 735.32	50.60.000.000.000.000	2,855.67 3,018.76	819.11 871.24	885.35 935.58	743.88 894.24	0.000,000,000,000,000	2,855.67 3,540.67
	(f) Depreciation and amortisation expense (g) Other expenses	4,748.51	4,257.02	4,131.46	16,484.52	14,716.17	8,440.36	7,552.70	7,044.05		25,772.89	869405156545657	S18 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	7,046.35	175.75 (1.15)	25,776.33
,	(g) Other expenses Total expenses (IV)	13,974.87	13,635.67	12,401.31	53,074.82	47,300.29	23,622.24	22,920.01	21,009.01	89,401.58	80,751.40	23,683.78	797.785.355.355	21,170.23	0.27 (24.07) (27.07)	81,276.75
V	Profit/(loss) before exceptional items and tax (III - IV)	3,581.81	1,838.28	2,499.83	14,729.99	9,941.71	2,403.07	1,540.29	2,484.67	11,334.47	11,193.30	2,341.54	100000000000000000000000000000000000000	2,323.45	1000 A 9 70 A 100 B 100 B 100 B	10,667.95
33.00	Exceptional items (Refer note 7)				(3,451.85)			1	1	(1,671.82)					(1,671.82)	
2000	Profit/(loss) before tax (V - VI)	3,581.81	1,838.28	2,499.83	*	9,941.71	2,403.07	1,540.29	2,484.67	13,006.29	11,193.30	2,341.54	1,435.63	2,323.45	* * * * * * * * * * * * * * * * * * * *	10,667.95
1000	Tax expense :	,	1338		1 22	1			1	8880	,		/	1		[]
	Current tax	848.44	309.32	598.40	3,834.95	2,018.21	874.25	629.89	961.43	4,765.42	3,256.90	874.25	629.89	948.64	4,765.42	3,244.11
,	Deferred tax	(79.51)	(165.26)	(22.30)	(536.14)	(735.11)	(87.80)	(253.01)	6.97	(1,009.06)	(102.30)	0.0000000000000000000000000000000000000	(270.93)	(135.56)	200000000000000000000000000000000000000	(318.99)
IX	Profit/(loss) for the period from continuing operations (VII-VIII)	2,812.88	1,694.22	1,923.73	14,883.03	8,658.61	1,616.62	1,163.41	1,516.27		6.7.66.50.01.00.000		1,076.67	1,510.37	8,916.70	500000000000000000000000000000000000000
X	Profit/(loss) before tax from discontinuing operations	87	398.25	440.86	2,028.34	2,246.54	1 87	1 59	(5)	- 1	- '		-'	4	4 -	4 2- 1
XI	Tax expense of discontinuing operations :	1		1		, , , , , , , , , , , , , , , , , , , ,	1	1	,	1	1		1	1	1	1 1
	Current tax	1	119.25	18,240,000,000	650.29	688.56	11	1 3	()	-/	1		- '	1	$A = \mathbb{F}'$	1 -17
	Deferred tax	- '	14.51	14.35	39.96	73.12	II I	-1	()	- /	- '	-	- '	1 -	1	1 -17
18090	Profit/(loss) for the period from discontinuing operations (X-XI)	4	264.49	291.39	1,338.09	1,484.86	1	1	()	-7	1	F- 1	- 1	1	1	1 - 1
	Profit/(loss) for the period for continuing and	0.010.00	1 050 71	0.015.10	10.004.40	10 140 47	1	1 100 41	1 510 07	2 242 02	2 000 70	4 500 07	1 070 07	1 510 07	201070	7740.00
	discontinuing operations (IX + XII)	2,812.88	1,958.71	2,215.12	16,221.12	10,143.47	1,616.62	1,163.41	1,516.27	9,249.93	8,038.70	1,562.97	1,076.67	1,510.37	8,916.70	7,742.83
	Other comprehensive income	(12.42)	(17.61)	26.41	(54.39)	(10.20)	(074.54)	(16.60)	1 000	(250.20)	41.06	(074.54)	(16.60)	0.02	(250.20)	41.06
, ,	A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be	(13.42)	(17.61)	36.41	(54.38)	(10.20)	(274.54)	(16.69)	9.93	(259.39)	41.96	(274.54)	(16.69)	9.93	(259.39)	41.96
, ,	reclassified to profit or loss	4.69	6.15	(12.60)	19.00	3.53	38.78	6.03	(9.15)	45.80	(3.25)	38.78	6.03	(9.15)	45.80	(3.25)
, ,	B (i) Items that will be reclassified to profit or loss	1.00	0.10	(12.00)	10.00	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(951.38)	566.06	(511.28)		(778.78)	0.0000000000000000000000000000000000000	200000000000000000000000000000000000000	(463.92)	1,000,000,000,000,000	(696.17)
, ,	(ii) Income tax relating to items that will be	1	.]	1	1	1		1	1	(0) ,	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(5.55,	,	(1.55.52)	(6,102.05)	(555)
,	reclassified to profit or loss	- '	-	-/		- 1	(300.25)	(56.92)	1	(229.50)	- '	(300.25)	(56.92)	-'	(229.50)	1
XV	Total comprehensive income	2,804.15	1,947.25	2,238.93	16,185.74	10,136.80			1,005.77	5,096.27	7,298.63		95007700000777	1,047.23		CONTROL OF THE REAL PROPERTY AND ADDRESS OF THE PROPERTY AND ADDRESS OF THE REAL PROPERTY AND ADDRESS OF THE PROPERTY AND ADDRESS OF THE PROPERTY AND ADDRESS OF THE PROPERTY ADDRESS OF THE PROPERTY AND ADDRESS OF THE PROPERTY AND ADDRESS OF THE PROPERTY ADDRESS OF THE PROPERTY AND ADDRESS OF THE PROPERTY ADDRESS OF THE PROPERTY AND ADDRESS OF THE PROPERTY AND ADDRESS OF THE PROPERTY ADDRESS OF TH
XVI	Total comprehensive income attributable to:	1	.]	1	1	1	1	1	1	1	1		1	1	1	1
, ,	- Non-controlling interests			-/	-	- 1	0.10	14. No. of the Co. of the Co.	0.47	0.11	0.92	1 (0.000)	VC11100000011717777777777	0.47	APP 100 (18 TO 18	0.92
	- Owners of the Company	2,804.15	1,947.25	2,238.93		10,136.80		1,661.80	1,005.30	A (100) (100) (100) (100) (100)	7,297.71	78.11	1,536.52	1,046.76	500000000000000000000000000000000000000	7,084.45
	Other equity	I	0	1	1,19,138.72	1,03,632.24	1	1 5	(5)	55,769.67	51,352.60	37		1	59,670.14	55,608.37
	Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised for quarters)						1!		1					[
	Basic EPS (in Rupees)	9.97	6.00	100000000000000000000000000000000000000	52.75	30.69	11 13.540 1	55565656	5.37		0.000000	2012 (2013)	0.500.000.000	5.35		27.44
335.11	Diluted EPS (in Rupees)	9.97	6.00	6.82	52.74	30.69	5.73	4.12	5.37	32.78	28.49	5.54	3.82	5.35	31.60	27.44
	Earning per share (EPS) (for discontinuing operations)	4	.]	1	1	1	11 /	1	,	1 '	1		1	1	1	1 '
	(of Re 1/- each) (not annualised for quarters) Basic EPS (in Rupees)	1 '	0.94	1.03	4.74	5.26	1	1		1	1		1	1	1 '	[
	Diluted EPS (in Rupees)	1 87	0.94	1.03	4.74	5.26	11	1 1	()	1 9	1	1	1	1 0	4 7	1
	Earning per share (EPS) (for continuing and discontinuing		0.54	1.00	4.74	3.20	1	[[20]	(5)	0/	1	1			1 20	
	operations) (of Re 1/- each) (not annualised for quarters)		1	1	1	<i>i</i>	1	1	1	1	1		1	1	1	1
	Basic EPS (in Rupees)	9.97	6.94	7.85	57.49	35.95	5.73	4.12	5.37	32.78	28.49	5.54	3.82	5.35	31.60	27.44
	Diluted EPS (in Rupees)	9.97	6.94			35.95	2000000	1000000	199700000	100000000000	100 100 100 100	200000	10000000	230,000		157555691333
		4	4	4			4						<u> </u>		4	-

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July, 2016. The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the IFRS in the format as per the Regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015.
- The above results were reviewed by the Audit Committee at its meeting held on 28 May, 2019 and approved at the meeting of the Board of Directors held on 29 May, 2019.
- 3 In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the statutory auditors have performed an audit of the standalone and consolidated financial results of the Company for the financial year ended 31 March, 2019. There are no modifications in the audit report.
- 4 The figures for the quarter ended 31 March are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the figures for the third quarter of the relevant financial year.
- 5 On 1 January 2019, the Company completed the transfer of the Company's Active Pharmaceuticals Ingredient (API) business to Glenmark Life Sciences Limited, a wholly owned subsidiary of the Company.
- 6 During the year, the Company bought back U.S.\$86,500,000 in aggregate principal amount of the Foreign Currency Convertible Bonds (FCCB). As of 31 March, 2019, U.S.\$113,500,000 in aggregate principal amount of FCCB are outstanding, resulting in gain on extinguishment of liability of Rs. 153.72 million.
- 7 Exceptional item: Exceptional items in the standalone (Ind AS) financial results for the year ended 31 March, 2019, primarily comprises of net gain of Rs. 3,451.85 million towards the sale of Orthopaedic and Pain management India business (Ortho India business). Exceptional items in the consolidated financial results (Ind AS and IFRS) for the year ended 31 March 2019 primarily comprises of the gain of Rs. 3,451.85 million towards the sale of Ortho India business and effect of de-prioritization of certain intangibles aggregating to Rs. 1,780.03 million.
- Post implementation of Goods and Service Tax ('GST') with effect from 1 July, 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in GST. Revenue from operations for year ended 31 March, 2018 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for quarter and year ended 31 March, 2019 are not comparable with previous periods presented.
- The disclosure of statement of assets and liabilities as per Regulation 33(3)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are an integral part of these results.
- 10 The Board has recommended a final dividend of 200% .i.e. Rs. 2 per equity share of face value of Re. 1 each for financial year 2018-19. The payment is subject to the approval of the shareholders in the ensuing annual general meeting.
- 11 Effective 1 April, 2018, the Company adopted Ind AS 115 or IFRS 15 "Revenue from Contracts with customers", as the case may be using the modified retrospective transition method. There was no material effect on the financial results on adoption of Ind AS 115 or IFRS 15, as the case may be.
- 12 The list of subsidiaries as of 31 March, 2019 is provided in Annexure A. 13 The Company operates in one reportable business segment i.e., Pharmaceuticals.
- 14 As at 31 March, 2019, pursuant to Employee Stock Options Scheme 2016, 4,59,414 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
- 15 Diluted EPS has been computed considering the effect of conversion of ESOPs.
- 16 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Glenmark Pharmaceuticals Limited

List of entities included in the consolidated financial results for the year ended 31 March 2019

 Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2.Glenmark Pharmaceuticals Europe Ltd., U.K. 3.Glenmark Pharmaceuticals S.R.O. 4.Glenmark Pharmaceuticals SK, S.R.O. 5.Glenmark Pharmaceuticals S. A. 6.Glenmark Holding S.A. 7.Glenmark Pharmaceuticals S.R.L. 8. Glenmark Pharmaceuticals SP z.o.o. 9. Glenmark Pharmaceuticals Inc. (formerly Glenmark Generics Inc.) 10. Glenmark Therapeutics Inc. 11.Glenmark Farmaceutica Ltda 12.Glenmark Generics S.A 13.Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 14.Glenmark Pharmaceuticals Peru SAC 15. Glenmark Pharmaceuticals Colombia SAS, Colombia (Formerly known as Glenmark Pharmaceuticals Colombia Ltda., Colombia) 16.Glenmark Uruguay S.A. 17.Glenmark Pharmaceuticals Venezuela, C.A 18.Glenmark Dominicana SRL 19.Glenmark Pharmaceuticals Egypt S.A.E. 20. Glenmark Pharmaceuticals FZE 21. Glenmark Impex L.L.C 22. Glenmark Philippines Inc. 23. Glenmark Pharmaceuticals (Nigeria) Ltd. 24.Glenmark Pharmaceuticals Malaysia Sdn Bhd 25.Glenmark Pharmaceuticals (Australia) Ptv Ltd 26.Glenmark South Africa (ptv) Ltd 27.Glenmark Pharmaceuticals South Africa (pty) Ltd 28.Glenmark Pharmaceuticals (Thailand) Co. Ltd 29.Glenmark Pharmaceuticals B.V.(Formerly known as Glenmark Generics B.V.) 30.Glenmark Arzneimittel Gmbh 31.Glenmark Pharmaceuticals Canada Inc. (formerly Glenmark Generics Canada Inc.) 32. Glenmark Pharmaceuticals Kenya Ltd 33. Glenmark Therapeutics AG 34. Viso Farmaceutica S.L., Spain 35. Glenmark Specialty SA 36. Glenmark Pharmaceuticals Distribution s.r.o. 37. Glenmark Pharmaceuticals Nordic AB 38. Glenmark Ukraine LLC 39.Glenmark-Pharmaceuticals Ecuador S.A. 40.Glenmark Pharmaceuticals Singapore Pte. Ltd. 41.Glenmark Biotherapeutics SA 42.Glenmark Life Sciences Limited (Formerly known as Zorg Laboratories Private Limited)

5.37

Total equity and liabilities

All amounts in million of Indian Rupees, unless otherwis	STAND	ALONE		CONSOLI	DATED	
	Ind AS As at 31.03.2019 Audited	Ind AS As at 31.03.2018 Audited	Ind AS As at 31.03.2019 Audited	Ind AS As at 31.03.2018 Audited	IFRS As at 31.03.2019 Audited	IFRS As at 31.03.2018 Audited
ASSETS						
Non current assets		Secret Harrison Secret	***************************************		50000000000000000000000000000000000000	
Property, plant and equipment	13,081.67	15,766.49	20,978.12	18,958.10	23,688.89	21,733.74
Capital work-in-progress	2,091.79	3,540.42	12,343.68	9,933.40	12,708.34	10,347.15
Goodwill	7.700.0000	50 A 10 C 10 C 10 C	547.35	521.04	547.35	521.04
Other intangible assets	1,053.16	1,224.73	15,177.07	10,816.38	17,289.96	13,296.47
Intangible assets under development	770.16	656.33	1,645.70	1,285.32	1,645.70	1,285.32
Financial assets	2007 (A) 2017 (A)	Shipson 3230	V2017C35/3803	340000000000000000000000000000000000000		
(i) Investments	32,687.52	32,126.84	296.59	146.61	296.59	146.61
(ii) Loans and advances	62,639.26	33,028.48		-		-
(iii) Other financial assets	368.01	380.91	501.87	401.18	501.87	401.18
Deferred tax assets (net)	7,121.33	6,606.15	13,829.51	13,202.60	12,905.43	12,201.76
Other non-current assets	202.54	565.85	599.77	802.23	236.00	389.36
Total non- current assets	1,20,015.44	93,896.20	65,919.66	56,066.86	69,820.13	60,322.63
Current assets						
Inventories	9,112.09	11,111.80	22,520.74	20,305.85	22,520.74	20,305.85
Financial assets						
(i) Investments		-	-	5-1	-	
(ii) Trade receivables	20,871.31	38,289.08	21,945.90	23,318.07	21,945.90	23,318.07
(iii) Cash and cash equivalents	2,549.97	1,760.47	9,362.78	12,333.56	9,362.78	12,333.56
(iv) Bank balance other than cash and cash equivalents	14.87	13.35	14.87	13.35	14.87	13.35
(v) Other financial assets	13,123.42	1,937.10	2,802.66	3,856.42	2,802.66	3,856.42
Current tax assets	-	.,		- 0,000	_,000.00	-
Other current assets	5,739.87	5,640.71	10,321.30	10,059.67	10,321.30	10,059.67
Total current assets	51,411.53	58,752.51	66,968.25	69,886.92	66,968.25	69,886.92
Total assets	1,71,426.97	1,52,648.71	1,32,887.91	1,25,953.78	1,36,788.38	1,30,209.55
EQUITY AND LIABILITIES	0.0000000000000000000000000000000000000					
Equity		11 101				
Equity share capital	282.17	282.17	282.17	282.17	282.17	282.17
Other equity	1,19,138.72	1,03,632.24	55,769.67	51,352.60	59,670.14	55,608.37
Minority interest	-	-	(3.77)	(3.70)	(3.77)	(3.70)
Liabilities			12 (C. C. C. C.	140000	0.75.500.500	M. Salate
Non-current liabilities						
Financial liabilities	200,000,000,000,000	0.0.00000000000000000000000000000000000	300000000000000000000000000000000000000		200220000000000000000000000000000000000	
(i) Borrowings	28,314.52	26,860.29	35,737.54	41,417.78	35,737.54	41,417.78
(ii) Other financial liabilities	885.06	26.00	885.06	26.00	885.06	26.00
Deferred tax liabilities (net)	-	-	-	-	-	
Other non- current liabilities	-	-	6.30		6.30	
Total non-current liabilities	29,199.58	26,886.29	36,628.90	41,443.78	36,628.90	41,443.78
Current liabilities						
Financial liabilities						
(i) Borrowings	3,030.30	2,950.44	3,030.24	2,950.44	3,030.24	2,950.44
(ii) Other financial liabilities	1,412.12	1,848.86	9,012.69	5,657.89	9,012.69	5,657.89
(iii) Trade payables						
- Total outstanding dues of other than Micro enterprises			NO. 100 (100 (100 (100 (100 (100 (100 (100			
and Small enterprises	15,787.57	14,571.28	21,097.52	17,719.59	21,097.52	17,719.59
- Total outstanding dues of Micro enterprises and						
Small enterprises	889.07	978.25	1,109.99	978.25	1,109.99	978.25
Other current liabilities	469.90	567.19	1,119.44	1,248.12	1,119.44	1,248.12
Provisions	853.30	783.58	4,383.50	4,040.38	4,383.50	4,040.38
Current tax liabilities (Net)	364.24	148.41	457.56	284.26	457.56	284.26
Total current liabilities	22,806.50	21,848.01	40.210.94	32,878.93	40,210.94	32,878.93
Total liabilities	52,006.08	48,734.30	76.839.84	74,322.71	76,839.84	74,322.71
Total aguity and liabilities	4 74 400 07	10,104.00	10,000.04	1 05 050 70	1 00 700 00	1 00 000 55

For and on behalf of the Board of Directors

1,71,426.97 1,52,648.71 1,32,887.91 1,25,953.78 1,36,788.38 1,30,209.55

Glenn Saldanha Chairman & Managing Director

Mumbai, 29 May, 2019